• Non ci sono risultati.

COMPOSITIONS BIOPHOTONIQUES POUR LE TRAITEMENT DE L'OTITE EXTERNE

N/A
N/A
Protected

Academic year: 2021

Condividi "COMPOSITIONS BIOPHOTONIQUES POUR LE TRAITEMENT DE L'OTITE EXTERNE"

Copied!
2
0
0

Testo completo

(1)

3/12/2018 Patent 3011156 Summary - Canadian Patents Database

http://www.ic.gc.ca/opic-cipo/cpd/eng/patent/3011156/summary.html?type=number_search&tabs1Index=tabs1_1 1/1 Home >  Canadian  Patent  Database>  Number  Search >  Patent  Summary

Canadian  Patents  Database

 /  Patent  3011156  Summary

Third-­party  information  liability Claims  and  Abstract  availability

(12)  Patent  Application: (11)  CA  3011156

(54)  English  Title: BIOPHOTONIC  COMPOSITIONS  FOR  THE  TREATMENT  OF  OTITIS  EXTERNA (54)  French  Title: COMPOSITIONS  BIOPHOTONIQUES  POUR  LE  TRAITEMENT  DE  L'OTITE  EXTERNE

(51)  International  Patent  Classification  (IPC): A61K  41/00  (2006.01)A61P  27/16  (2006.01)

(72)  Inventors  (Country):

BELLINI,  FRANCESCO  (Canada) CERQUETELLA,  MATTEO  (Italy) TAMBELLA,  ADOLFO  MARIA  (Italy) SPATERNA,  ANDREA  (Italy)

LOUPIS,  NIKOLAOS  (Greece) OHAYON,  DAVID  (Canada) PIERGALLINI,  REMIGIO  (Italy)

(73)  Owners  (Country):

KLOX  TECHNOLOGIES  LIMITED  (Ireland) BELLINI,  FRANCESCO  (Canada)

CERQUETELLA,  MATTEO  (Italy) TAMBELLA,  ADOLFO  MARIA  (Italy) SPATERNA,  ANDREA  (Italy)

LOUPIS,  NIKOLAOS  (Greece) OHAYON,  DAVID  (Canada) PIERGALLINI,  REMIGIO  (Italy)

(71)  Applicants  (Country):

KLOX  TECHNOLOGIES  LIMITED  (Ireland) BELLINI,  FRANCESCO  (Canada)

CERQUETELLA,  MATTEO  (Italy) TAMBELLA,  ADOLFO  MARIA  (Italy) SPATERNA,  ANDREA  (Italy)

LOUPIS,  NIKOLAOS  (Greece) OHAYON,  DAVID  (Canada) PIERGALLINI,  REMIGIO  (Italy)

(74)  Agent: BCF  LLP

(45)  Issued:

(86)  PCT  Filing  Date: 2017-­01-­11 (87)  PCT  Publication  Date: 2017-­07-­20 (30)  Availability  of  licence: N/A

(30)  Language  of  filing: English Patent  Cooperation  Treaty  (PCT): Yes

(86)  PCT  Filing  Number: PCT/CA2017/050032 (87)  International  Publication  Number: WO2017/120671

(85)  National  Entry: 2018-­07-­09 (30)  Application  Priority  Data:

Application  No. Country Date

62/277,263 United  States  of  America 2016-­01-­11

Canadian  Intellectual  Property  Office

         

(2)

3/12/2018 Patent 3011156 Summary - Canadian Patents Database

http://www.ic.gc.ca/opic-cipo/cpd/eng/patent/3011156/summary.html?type=number_search&tabs1Index=tabs1_1 1/1 Home >  Canadian  Patent  Database>  Number  Search >  Patent  Summary

Canadian  Patents  Database

 /  Patent  3011156  Summary

Third-­party  information  liability Claims  and  Abstract  availability

(12)  Patent  Application: (11)  CA  3011156

(54)  English  Title: BIOPHOTONIC  COMPOSITIONS  FOR  THE  TREATMENT  OF  OTITIS  EXTERNA (54)  French  Title: COMPOSITIONS  BIOPHOTONIQUES  POUR  LE  TRAITEMENT  DE  L'OTITE  EXTERNE

English  Abstract

The  present  disclosure  describes  methods  and  uses  of  biophotonic  compositions  which  comprise  at  least  one  oxidant  and  at  least  one  chromophore capable  of  activating  the  oxidant,  in  association  with  a  pharmacologically  acceptable  carrier  for  the  treatment  of  otitis  externa.

French  Abstract

La  présente  invention  concerne  des  procédés  et  des  utilisations  de  compositions  biophotoniques  qui  contiennent  au  moins  un  oxydant  et  au  moins un  chromophore  apte  à  activer  l'oxydant,  en  association  avec  un  excipient  pharmaceutiquement  acceptable  pour  le  traitement  de  l'otite  externe.

Canadian  Intellectual  Property  Office

         

Riferimenti

Documenti correlati

By adopting a VSD approach to the design of molecular manufacturing the values held by stakeholders at all socio-economic statuses can be accounted for and incorporated into the

The comparison between the measured differential cross section for the associated production of a Z boson and exactly one b jet and the theoretical predictions provided both by

In particular, a historical analysis was carried out, focusing on the three leading firms operating in the mobile gaming industry, Rovio (with Angry Birds), Zynga (with

However, optimal test performance was achie- ved when the recommended, definitively diagnostic, 4-fold elevation criterion for plasma fractionated metanephrines was supplemented

Owing to its self-organizing capability, it works without prior assumptions on either the frequency dependence or the angular power spectrum of the various signals; rather, it

In particular, the present work reviews the pathophysiological role of Kv7 channels in neuronal function, the molecular mechanisms involved in the Kv7 channel-opening action

A Longitudinal Study on the Relationship Between Aerobic Endurance and Lower Body Strength in Italian Sedentary Older Adults..

set of three-dimensional subjects corresponding to a common time point Where said computation is a func tion of at least one visual composition property of at least